Results 181 to 190 of about 141,802 (323)

Publisher Correction: Comparative lipidome and transcriptome provide novel insights into zero-valent iron nanoparticle-treated Fremyella diplosiphon. [PDF]

Sci Rep
Yalcin YS, Gichuki S, Chen H, Arumanayagam AS, Malwalage SM, Sitther V.   +5 more
europepmc   +1 more source

The subcellular distribution of phosphorylated Y‐box‐binding protein‐1 at S102 in colorectal cancer patients, stratified by KRAS mutational status and clinicopathological features

Molecular Oncology, EarlyView.
This study identifies nuclear YB‐1 S102 phosphorylation as a marker associated with KRAS and FBXW7 mutations in colorectal cancer. Mutated KRAS correlates specifically with nuclear, not cytoplasmic, S102 YB‐1. These findings provide the first ex vivo evidence of this link in CRC and suggest future studies should assess the prognostic and therapeutic ...
Konstanze Lettau, Stephan Forchhammer, Birgit Fehrenbacher, Lejla Mahmutovic, Marcus Scharpf, Gunnar Blumenstock, Martin Schaller, Irina Bonzheim, Shayan Khozooei, Mahmoud Toulany   +9 more
wiley   +1 more source

Construction of Dynamic Hydrogel Inducing Effective and Selective 5-Fluorouracil Monotherapy against Cervical Cancer Cells. [PDF]

ACS Appl Mater Interfaces
Gosecka M, Jaworska-Krych D, Gosecki M, Urbaniak M, Wielgus E, Gostynski B, Marcinkowska M, Janaszewska A, Klajnert-Maculewicz B.   +8 more
europepmc   +1 more source

Interaction of an Endotoxin with Cationic Macromolecules

, 1961
P T Mora, Bobby G. Young
openalex   +1 more source

Remark on Yamakawa—Fujii’s Paper Concerning the Intrinsic Viscosity of Rod-like Macromolecules [PDF]

, 1975
Nobuko Taki
openalex   +1 more source

A nucleotide‐independent, pan‐RAS‐targeted DARPin elicits anti‐tumor activity in a multimodal manner

Molecular Oncology, EarlyView.
We report a Designed Ankyrin Repeat Protein that binds and inhibits RAS proteins, which serve as central cell signaling hubs and are essential for the progression of many cancers. Its unique feature is that it does not discriminate between different RAS isoforms or mutations and is capable of binding to RAS in both its active (GTP‐bound) and inactive ...
Jonas N. Kapp, Wouter P. R. Verdurmen, Jonas V. Schaefer, Kari Kopra, Gabriela Nagy‐Davidescu, Elodie Richard, Marie‐Julie Nokin, Patrick Ernst, Rastislav Tamaskovic, Martin Schwill, Ralph Degen, Claudia Scholl, David Santamaria, Andreas Plückthun   +13 more
wiley   +1 more source

Pharmaceutical Analysis of Protein-Peptide Coformulations and the Influence of Polysorbates. [PDF]

Mol Pharm
Whiteley J, Abrahmsén-Alami S, Booth J, Mellor S, Humphrey J, Waters LJ.   +5 more
europepmc   +1 more source

Evolutionary adaptability of biological macromolecules [PDF]

, 1977
Michael Conrad
openalex   +1 more source

Therapeutic applications of a novel humanized monoclonal antibody targeting chemokine receptor CCR9 in pancreatic cancer

Molecular Oncology, EarlyView.
C–C chemokine receptor type 9 (CCR9) is an immune checkpoint in pancreatic ductal adenocarcinoma (PDAC). Novel anti‐CCR9 antibody SRB2 was evaluated in combination with cytotoxic chemotherapy in PDAC cells, patient‐derived organoids, patient‐derived xenografts, and humanized mouse models.
Hannah G. McDonald, Anna M. Reagan, Charles J. Bailey, Mei Gao, Muqiang Gao, Angelica L. Solomon, Michael J. Cavnar, Prakash K. Pandalai, Mautin T. Barry‐Hundeyin, Megan M. Harper, Justin A. Rueckert, Ángela Turrero, Araceli Tobio, Anxo Vidal, Daniel Roca‐Lema, Elia Álvarez‐Coiradas, Pablo Garrido, Laureano Simón, Joseph Kim   +18 more
wiley   +1 more source

Can breakthroughs in dermal and transdermal macromolecule delivery surmount existing barriers and revolutionize future therapeutics? [PDF]

J Transl Med
Bhat M, Tharmatt A, Bhargava S, Kumeria T, Mishra A, Mittal A, Chitkara D.   +6 more
europepmc   +1 more source